Latest News and Press Releases

No safety concerns in first two patients treatedDesigned to accelerate T-cell reconstitution following haploidentical Hematopoietic Stem Cell Transplantation (HSCT) with post-transplant...

Aucune toxicité observée chez les deux premiers patients traités SMART101 est conçu pour accélérer la reconstitution immunitaire après une greffe de cellules souches haplo-identique suivie d’un...

Smart Immune to present details of the phase I/II studies of new T-cell therapy SMART101 at the European Hematology Association (EHA) Two poster presentations at EHA showcase ProTcell, an innovative...

Smart Immune receives $5 million investment to further its thymus-empowered ProTcell therapy platform The new funding from the Gates Foundation will advance a Phase 1/2 clinical trial of an...

Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator PARIS, France, 30 March, 2023 – Smart Immune SAS, a...

Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator PARIS, France, 30 March, 2023 – Smart Immune SAS, a...

Smart Immune is selected for the first cohort of the French Tech Health20 program This unique program has selected 20 French start-ups that offer disruptive healthcare innovations PARIS, France,...

Smart Immune appoints world-class Clinical Advisory Board PARIS, France, November 21, 2022 – Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell™, a pioneering new approach...

Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers First trial...

Smart Immune Bolsters Management Team with Medical and Technical Appointments Dr Frederic Lehmann, MD, appointed Chief Medical Officer and Dr Pierre Heimendinger, PharmD, appointed Chief Technical...